Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DM2Y5AP)

Drug Name

N-(3,3-Dimethyl-butyl)-4-hexyloxy-benzamide Drug Info

Synonyms

CHEMBL122341; N-(3,3-Dimethyl-butyl)-4-hexyloxy-benzamide; ZINC13864671; BDBM50106166

Indication

Disease Entry	ICD 11	Status	REF
Discovery agent	N.A.	Investigative	[1]

Cross-matching ID

Molecule-Related Drug Atlas

Molecule Type:

DTT

Drug Status:

Approved Drug(s)

Discontinued Drug(s)

Investigative Drug(s)

Download the Complete Related Drug List

Drug(s) Targeting Voltage-gated potassium channel Kv7.1 (KCNQ1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Indapamide	DMGN1PW	Edema	MG29	Approved	[2]
L-768673	DMZ402C	N. A.	N. A.	Terminated	[3]
zinc pyrithione	DMF0CRA	Discovery agent	N.A.	Investigative	[4]
XE991	DMLH1PK	Discovery agent	N.A.	Investigative	[5]
N-(3,3-Dimethyl-cyclopentyl)-4-hexyloxy-benzamide	DM6EJQ4	Discovery agent	N.A.	Investigative	[1]
(3R,4S)-293B	DM47BEG	Discovery agent	N.A.	Investigative	[6]
HMR-1556	DMXMTA9	Discovery agent	N.A.	Investigative	[7]
R-L3	DMGEDQJ	Discovery agent	N.A.	Investigative	[8]
3S,4R-293B	DMVGDSM	Discovery agent	N.A.	Investigative	[6]
N-(3,3-Dimethyl-butyl)-4-indol-1-yl-benzamide	DMEUXOQ	Discovery agent	N.A.	Investigative	[1]
------------------------------------------------------------------------------------


⏷ Show the Full List of 10 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Download the Complete Interaction Atlas for Visualization in Cytoscape

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Voltage-gated potassium channel Kv7.1 (KCNQ1)	TT846HF	KCNQ1_HUMAN	Inhibitor	[1]

------------------------------------------------------------------------------------

References

1	Design and synthesis of 4-substituted benzamides as potent, selective, and orally bioavailable I(Ks) blockers. J Med Chem. 2001 Nov 8;44(23):3764-7.
2	Indapamide induces apoptosis of GH3 pituitary cells independently of its inhibition of voltage-dependent K+ currents. Eur J Pharmacol. 2006 Apr 24;536(1-2):78-84.
3	Class III antiarrhythmic activity in vivo by selective blockade of the slowly activating cardiac delayed rectifier potassium current IKs by (R)-2-(... J Med Chem. 1997 Nov 21;40(24):3865-8.
4	Zinc pyrithione-mediated activation of voltage-gated KCNQ potassium channels rescues epileptogenic mutants. Nat Chem Biol. 2007 May;3(5):287-96.
5	Molecular basis for differential sensitivity of KCNQ and I(Ks) channels to the cognitive enhancer XE991. Mol Pharmacol. 2000 Jun;57(6):1218-23.
6	A kinetic study on the stereospecific inhibition of KCNQ1 and I(Ks) by the chromanol 293B. Br J Pharmacol. 2001 Dec;134(8):1647-54.
7	Selective optimization of side activities: another way for drug discovery. J Med Chem. 2004 Mar 11;47(6):1303-14.
8	A novel benzodiazepine that activates cardiac slow delayed rectifier K+ currents. Mol Pharmacol. 1998 Jul;54(1):220-30.